Skip to main content

Table 2 Baseline characteristics of included patients

From: A new method for treating fecal incontinence by implanting stem cells derived from human adipose tissue: preliminary findings of a randomized double-blind clinical trial

Variable

Total

Control group

hADSC-treated group

p

Age (median, IQR)

40.2 (25)

38.5 (22)

36.0 (22)

0.45*

Gender (n, %)

 Male

4 (22.22)

2 (22.22)

2 (22.22)

0.71#

 Female

14 (77.78)

7 (77.78)

7 (77.78)

 

History of GI diseases (n, %)

 No

13 (72.22)

6 (77.78)

6 (66.67)

>0.99#

 Yes

5 (27.78)

2 (22.22)

3 (33.33)

 

Number of deliveries (n, %)

 0

7 (41.18)

2 (25.0)

5 (55.56)

0.22#

 1

7 (41.18)

5 (62.50)

2 (22.22)

 

 2

2 (11.78)

0 (0.0)

2 (22.22)

 

 3

1 (5.88)

1 (12.50)

0 (0.0)

 

Rectal urgency (n, %)

 No

18 (100.0)

9 (100.0)

9 (100.0)

>0.99#

 Yes

0 (0.0)

0 (0.0)

0 (0.0)

 

History of anal surgery (n, %)

 No

11 (61.11)

5 (55.56)

6 (66.67)

>0.99#

 Yes

7 (38.89)

4 (44.44)

3 (33.33)

 

History of urinary urgency (n, %)

 No

18 (100.0)

9 (100.0)

9 (100.0)

>0.99#

 Yes

0 (0.0)

0 (0.0)

0 (0.0)

 
  1. IQR interquartile range, GI gastrointestinal, control group sphincteroplasty alone, hADSC-treated group human adipose-derived stem cells + sphincteroplasty
  2. *Based on Mann–Whitney U test
  3. #Based on Fisher’s exact test